Opthea (CKDXF) Price & Analysis

Compare

16 Followers

CKDXF Stock Chart & Stats

$0.48

-$0.13(-22.81%)

At close: Nov 14 4:00 PM EST

$0.48

-$0.13(-22.81%)

Day’s Range― - ―

52-Week Range$0.35 - $0.48

Previous CloseN/A

Volume9.90K

Average Volume (3M)0.00

Market Cap

$489.14M

Enterprise ValueN/A

Total Cash (Recent Filing)$131.92M

Total Debt (Recent Filing)$157.25M

Price to Earnings (P/E)―

Beta0.22

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding1,367,978,100

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Opthea News

Opthea to Host Corporate Update Webinar

Opthea ( ($AU:OPT) ) just unveiled an update. Opthea Limited announced it will provide a corporate update on...

5d ago

Opthea Limited Secures Shareholder Approval for Key Resolutions

Opthea ( ($AU:OPT) ) has shared an announcement. Opthea Limited announced the successful passage of all resolutions at...

1M ago

Opthea Streamlines Operations and Strengthens Financial Position

The latest announcement is out from Opthea ( ($AU:OPT) ). Opthea Limited has simplified its operations and resolved...

2M ago

Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market

The latest announcement is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced its decision to voluntarily...

2M ago

Opthea Announces Key Management Appointments

The latest update is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced the appointment of Mr....

2M ago

Opthea Secures A$10.8 Million R&D Tax Incentive to Boost Innovation

The latest update is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced the receipt of an...

2M ago

Opthea Announces Annual General Meeting Date and Director Nomination Deadline

Opthea ( ($AU:OPT) ) has shared an update. Opthea Limited has announced that its Annual General Meeting will...

3M ago

Opthea Releases 2025 Corporate Governance Statement

Opthea ( ($AU:OPT) ) has provided an announcement. Opthea Limited has released its Corporate Governance Statement for the...

3M ago

Opthea’s Bold Strategy in Pharmaceutical Innovation

The latest announcement is out from Opthea ( ($AU:OPT) ). Opthea is a company operating in the pharmaceutical...

3M ago

S&P/ASX Indices Rebalance Announced for September 2025

Opthea ( ($AU:OPT) ) just unveiled an update. S&P Dow Jones Indices, a leading global resource for index-based...

3M ago

Opthea terminates COAST trial, announces ShORe trial misses endpoint

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline...

9M ago

OPT

Opthea downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Opthea (OPT) to Perform from Outperform. Published first on TheFly – the ultimate source for real-time,...

9M ago

OPT

Opthea downgraded to Market Perform from Outperform at Leerink

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform. Published first on TheFly – the...

9M ago

OPT

Opthea cut to Market Perform at Leerink on failed sozinibercept trial

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12....

9M ago

OPT

CKDXF FAQ

What was Opthea Limited’s price range in the past 12 months?

Opthea Limited lowest stock price was $0.35 and its highest was $0.48 in the past 12 months.

What is Opthea Limited’s market cap?

Opthea Limited’s market cap is $489.14M.

When is Opthea Limited’s upcoming earnings report date?

Opthea Limited’s upcoming earnings report date is Feb 26, 2026 which is in 71 days.

How were Opthea Limited’s earnings last quarter?

Opthea Limited released its earnings results on Aug 29, 2025. The company reported -$0.027 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.018.

Is Opthea Limited overvalued?

According to Wall Street analysts Opthea Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Opthea Limited pay dividends?

Opthea Limited does not currently pay dividends.

What is Opthea Limited’s EPS estimate?

Opthea Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Opthea Limited have?

Opthea Limited has 1,367,978,100 shares outstanding.

What happened to Opthea Limited’s price movement after its last earnings report?

Opthea Limited reported an EPS of -$0.027 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Opthea Limited?

Currently, no hedge funds are holding shares in CKDXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opthea Stock Smart Score

Neutral

Blogger Sentiment

Bullish

CKDXF Sentiment 70%
Sector Average 68%

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-69.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.